Synergistic interaction of hyperthermia and gemcitabine in lung cancer

Cancer Biology and Therapy

Volumn 4, Issue 10, 2005, Pages 1144-1153

  Vertrees, Roger A ^a   Das, Gokul C ^a   Popov, Vsevolod L ^a   Coscio, Angela M ^a   Goodwin, Thomas J ^b   Logrono, Roberto ^a   Zwischenberger, Joseph B ^a   Boor, Paul J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NASA JOHNSON SPACE CENTER   (United States)

Author keywords

Apoptosis; Caspase 3; Gemcitabine; Hyperthermia; Lung cancer; Synergistic

Indexed keywords

CASPASE 3; GEMCITABINE; HEAT SHOCK PROTEIN 70; LIPOCORTIN 5;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE G2 PHASE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERTHERMIA; LUNG CANCER; MITOSIS INDEX; MOUSE STRAIN; STAINING; SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; WESTERN BLOTTING;

EID: 27744446358     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.10.2074     Document Type: Article

References (46)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Bunn Jr PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for nonsmall cell lung cancer: A time for reassessment? Chest 2000; 117:119S-22S.
3. Medley L, Cullen M. Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer. Curr Opin Oncol 2002; 14:384-8.
4. Bunn Jr PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: Biology and molecular biology come of age. Chest 2000; 117:163S-8S.
5. Twombly R. FDA oncology committee debates Iressa's status following negative trial results. J Natl Cancer Inst 2005; 97:473.
6. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with nonsmall-cell lung cancer. J Clin Oncol 2004; 22:3238-47.
7. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H. S-1 plus cisplatin combination chemotherapy in patients with advanced nonsmall cell lung cancer: A multi-institutional phase II trial. Clin Cancer Res 2004; 10:7860-4.
8. Zwischenberger JB, Vertrees RA, Woodson LC, Bedell EA, Alpard SK, McQuitty CK, Chernin JM. Percutaneous venovenous perfusion-Induced systemic hyperthermia for advanced nonsmall cell lung cancer: Initial clinical experience. Ann Thorac Surg 2001; 72:234-43.
9. van der Zee J. Heating the patient: A promising approach? Ann Oncol 2002; 13:1173-84.
10. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10:463-8.
11. Nagle VLJ, Berry JM, Bull JM. Whole body hyperthermia with carboplatin (CBDCA) for treatment of advanced or metastatic GI adenocarcinomas. Proc Am Assoc CA Res 1999; 40:345.
12. Vertrees RA, Zwischenberger JB, Boor PJ, Pencil SD. Oncogenic ras results in increased cell kill due to defective thermoprotection in lung cancer cells. Ann Thorac Surg 2000; 69:1675-80.
13. 2-phase delays after irradiation and/or heat treatment as assessed by two-parameter flow cytometry. Radiat Res 2001; 155:50-6.
14. Higashikubo R, Holland JM, Roti Roti JL. Comparative effects of caffeine on radiation-and heat-induced alterations in cell cycle progression. Radiat Res 1989; 119:246-60.
15. Dewey WC, Li XL, Wong RS. Cell killing, chromosomal aberrations, and division delay as thermal sensitivity is modified during the cell cycle. Radiat Res 1990; 122:268-74.
16. He N, Li C, Zhang X, Sheng T, Chi S, Chen K, Wang Q, Vertrees R, Logrono R, Xie J. Regulation of lung cancer cell growth and invasiveness by beta-TRCP. Mol Carcinog 2005; 42:18-28.
17. Parks LC, Minaberry D, Smith DP, Neely WA. Treatment of far-advanced bronchogenic carcinoma by extracorporeally induced systemic hyperthermia. J Thorac Cardiovasc Surg 1979; 78:883-92.
18. Zwischenberger JB, Vertrees RA, Bedell EA, McQuitty CK, Chernin JM, Woodson LC. Percutaneous venovenous Perfusion-Induced systemic hyperthermia for lung cancer: A phase I safety study. Ann Thorac Surg 2004; 77:1916-25.
19. Pereira S, Fernandes PA, Ramos MJ. Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. J Comput Chem 2004; 25:1286-94.
20. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced nonsmall cell lung cancer patients. Clin Cancer Res 2004; 10:1318-25.
21. Pace E, Melis M, Siena L, Bucchieri F, Vignola AM, Profita M, Gjomarkaj M, Bonsignore G. Effects of gemcitabine on cell proliferation and apoptosis in nonsmall-cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 2000; 46:467-76.
22. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, Pommier Y. Gemcitabine (2′,2′-difluoro= 2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002; 8:2499-504.
23. Fennell DA. Caspase regulation in nonsmall cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res 2005; 11:2097-105.
24. Van Bree C, Beumer C, Rodermond HM, Haveman J, Bakker PJM. Effectiveness of 2′,2′ difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 1999; 15:549-56.
25. Haveman J, Hahn GM. The role of energy in hyperthermia-induced mammalian cell inactivation: A study of the effects of glucose starvation and an uncoupler of oxidative phosphorylation. J Cell Physiol 1981; 107:237-41.
26. Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995; 62:627-30.
27. Yoakum GH, Lechner JF, Gabrielson EW, Korba BE, Malan-Shibley L, Willey JC, Valerio MG, Shamsuddin AM, Trump BF, Harris CC. Transformation of human bronchial epithelial cells transfected by Harvey ras oncogene. Science 1985; 227:1174-9.
28. Amstad P, Reddel RR, Pfeifer A, Malan-Shibley L, Mark IIIrd GE, Harris CC. Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral Harvey ras. Mol Carcinog 1988; 1:151-60.
29. Goodwin TJ, Prewett TL, Wolf DA, Spaulding GF. Reduced shear stress: A major component in the ability of mammalian tissues to form three-dimensional assemblies in simulated microgravity. J Cell Biochem 1993; 51:301-11.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
31. Vertrees RA, Zwischenberger JB, Boor PJ. Optimized synergistic effect when hyperthermia precedes 2′, 2′ Difluorodeoxycytidine (dFdC, Gemcitabine) by 24 hours. Proc Am Assoc CA Res 2001; 42:#1973.
32. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5:85-91.
33. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001; 7:2887-97.
34. Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: A phase II trial of the North Central Cancer Treatment Group. Cancer 2003; 97:2498-503.
35. Tomasovic SP, Barta M, Klostergaard J. Neutral red uptake and clonogenic survival assays of the hyperthermic sensitization of tumor cells to tumor necrosis factor. Radiat Res 1989; 119:325-37.
36. Vertrees RA, Deyo DJ, Quast M, Lightfoot KM, Boor PJ, Zwischenberger JB. Development of human to murine orthotopic xenotransplanted lung cancer model. J Invest Surg 2000; 13:349-58.
37. Li GC, Li L, Liu RY, Rehman M, Lee WM. Heat shock protein hsp70 protects cells from thermal stress even after deletion of its ATP-binding domain. Proc Natl Acad Sci USA 1992; 89:2036-40.
38. Jones EL, Zhao MJ, Stevenson MA, Calderwood SK. The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer. Int J Hyperthermia 2004; 20:835-49.
39. Nakao K, Otsuki Y, Akao Y, Ito Y, Marukawa O, Tachibana S, Kawakami M, Sasaki S. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electron Microsc 2000; 33:44-50.
40. Green DR. Apoptotic pathways: The roads to ruin. Cell 1998; 94:695-8.
41. Jaattela M, Wissing D, Kokholm K, Kallunki T, Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J 1998; 17:6124-34.
42. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, Jaggi R, Marti A. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000; 60:4386-90.
43. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36:131-49.
44. Moller MB. Molecular control of the cell cycle in cancer: Biological and clinical aspects. Dan Med Bull 2003; 50:118-38.
45. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001; 7:2168-81.
46. Mose S, Class R, Weber HW, Rahn A, Brady LW, Bottcher HD. Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 2003; 26:60-9.